These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 36442615)
21. Cannabinoid withdrawal in mice: inverse agonist vs neutral antagonist. Tai S; Nikas SP; Shukla VG; Vemuri K; Makriyannis A; Järbe TU Psychopharmacology (Berl); 2015 Aug; 232(15):2751-61. PubMed ID: 25772338 [TBL] [Abstract][Full Text] [Related]
22. Targeting the endocannabinoid/CB1 receptor system for treating obesity in Prader-Willi syndrome. Knani I; Earley BJ; Udi S; Nemirovski A; Hadar R; Gammal A; Cinar R; Hirsch HJ; Pollak Y; Gross I; Eldar-Geva T; Reyes-Capo DP; Han JC; Haqq AM; Gross-Tsur V; Wevrick R; Tam J Mol Metab; 2016 Dec; 5(12):1187-1199. PubMed ID: 27900261 [TBL] [Abstract][Full Text] [Related]
23. A new perspective of cannabinoid 1 receptor antagonists: approaches toward peripheral CB1R blockers without crossing the blood-brain barrier. Wu YK; Yeh CF; Ly TW; Hung MS Curr Top Med Chem; 2011; 11(12):1421-9. PubMed ID: 21510837 [TBL] [Abstract][Full Text] [Related]
24. Effects of a Peripherally Restricted Hybrid Inhibitor of CB1 Receptors and iNOS on Alcohol Drinking Behavior and Alcohol-Induced Endotoxemia. Santos-Molina L; Herrerias A; Zawatsky CN; Gunduz-Cinar O; Cinar R; Iyer MR; Wood CM; Lin Y; Gao B; Kunos G; Godlewski G Molecules; 2021 Aug; 26(16):. PubMed ID: 34443679 [TBL] [Abstract][Full Text] [Related]
25. The therapeutic potential of second and third generation CB Cinar R; Iyer MR; Kunos G Pharmacol Ther; 2020 Apr; 208():107477. PubMed ID: 31926199 [TBL] [Abstract][Full Text] [Related]
26. Cannabinoid 1 G protein-coupled receptor (periphero-)neutral antagonists: emerging therapeutics for treating obesity-driven metabolic disease and reducing cardiovascular risk. Janero DR; Lindsley L; Vemuri VK; Makriyannis A Expert Opin Drug Discov; 2011 Oct; 6(10):995-1025. PubMed ID: 22646861 [TBL] [Abstract][Full Text] [Related]
28. Reversal of diet-induced hepatic steatosis by peripheral CB1 receptor blockade in mice is p53/miRNA-22/SIRT1/PPARα dependent. Azar S; Udi S; Drori A; Hadar R; Nemirovski A; Vemuri KV; Miller M; Sherill-Rofe D; Arad Y; Gur-Wahnon D; Li X; Makriyannis A; Ben-Zvi D; Tabach Y; Ben-Dov IZ; Tam J Mol Metab; 2020 Dec; 42():101087. PubMed ID: 32987186 [TBL] [Abstract][Full Text] [Related]
29. Low brain CB1 receptor occupancy by a second generation CB1 receptor antagonist TM38837 in comparison with rimonabant in nonhuman primates: a PET study. Takano A; Gulyás B; Varnäs K; Little PB; Noerregaard PK; Jensen NO; Elling CE; Halldin C Synapse; 2014 Mar; 68(3):89-97. PubMed ID: 24293119 [TBL] [Abstract][Full Text] [Related]
30. CB1 receptor antagonist rimonabant protects against chronic intermittent hypoxia-induced bone metabolism disorder and destruction in rats. Dou ZJ; Gao XL; Jia YL; Chen J; Yang JJ; Chen Y; Wu SJ; Liu T; Wang MT; Yang C; Zhang N; Wang B Sleep Breath; 2020 Dec; 24(4):1441-1449. PubMed ID: 31898189 [TBL] [Abstract][Full Text] [Related]
31. Role of Cannabinoid Receptor Type 1 in Insulin Resistance and Its Biological Implications. Nagappan A; Shin J; Jung MH Int J Mol Sci; 2019 Apr; 20(9):. PubMed ID: 31035653 [TBL] [Abstract][Full Text] [Related]
32. Cannabinoid type 1 receptor blockade induces transdifferentiation towards a brown fat phenotype in white adipocytes. Perwitz N; Wenzel J; Wagner I; Büning J; Drenckhan M; Zarse K; Ristow M; Lilienthal W; Lehnert H; Klein J Diabetes Obes Metab; 2010 Feb; 12(2):158-66. PubMed ID: 19895638 [TBL] [Abstract][Full Text] [Related]
33. CB(1) blockade-induced weight loss over 48 weeks decreases liver fat in proportion to weight loss in humans. Bergholm R; Sevastianova K; Santos A; Kotronen A; Urjansson M; Hakkarainen A; Lundbom J; Tiikkainen M; Rissanen A; Lundbom N; Yki-Järvinen H Int J Obes (Lond); 2013 May; 37(5):699-703. PubMed ID: 22828945 [TBL] [Abstract][Full Text] [Related]
34. Rimonabant improves metabolic parameters partially attributed to restoration of high voltage-activated Ca2+ channels in skeletal muscle in HFD-fed mice. Chen B; Hu N Braz J Med Biol Res; 2017 May; 50(6):e6141. PubMed ID: 28492810 [TBL] [Abstract][Full Text] [Related]
35. Neutral CB1 Receptor Antagonists as Pharmacotherapies for Substance Use Disorders: Rationale, Evidence, and Challenge. Soler-Cedeno O; Xi ZX Cells; 2022 Oct; 11(20):. PubMed ID: 36291128 [TBL] [Abstract][Full Text] [Related]
36. CB1 receptor antagonist rimonabant protects against chronic intermittent hypoxia-induced renal injury in rats. Zhao L; Liu T; Dou ZJ; Wang MT; Hu ZX; Wang B BMC Nephrol; 2021 Apr; 22(1):153. PubMed ID: 33902473 [TBL] [Abstract][Full Text] [Related]